Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

182 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-19

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The trial will be conducted to evaluate the safety and efficacy of the BeGraft Peripheral Stent Graft System in interventional revascularisation for subjects with primary iliac artery stenosis and/or occlusive lesions by conducting a multi-centre, randomised controlled clinical study with a bare metal stent system as the control, thus providing a basis for the formal use of the product in China

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System

NCT02211716

Peripheral Vascular Disease

COMPLETED PHASE4

Safety and Effectiveness of the Peripheral Balloon-Expandable Covered Stent System for Iliac Artery Stenosis/Occlusion. (SELECT)

NCT06605209

Peripheral Artery Disease (PAD)

RECRUITING NA

Safety and Efficacy Study of Iliac Bifurcation Stent Graft System

NCT03686189

Aortoiliac Aneurysm Iliac Aneurysm

UNKNOWN NA

The Study on the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System

NCT06660927

Common Iliac Artery Aneurysm

ACTIVE_NOT_RECRUITING NA

A First-in-Man Clinical Trial to Evaluate the Safety and Feasibility of ICS-Elpis in Patients With Iliac Artery Stenosis or Occlusion Lesions

NCT07290101

Iliac Artery Stenosis Iliac Artery Occlusion

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study adopts a prospective, multi-centre, randomised controlled trial design, aiming at evaluating the efficacy and safety of the BeGraft Peripheral Stent Graft System for primary iliac artery stenosis and/or occlusive lesions. A total of 182 subjects are planned to be enrolled, with all consecutively enrolled subjects being randomly assigned to an experimental group (BeGraft group, n=91) and a control group (bare metal stent group, n=91) in the ratio of 1:1 and respectively treated using the BeGraft Peripheral Stent Graft System and the bare metal stent system. Follow-up visits are carried out for the above-mentioned 182 subjects at baseline, upon discharge from hospital, at 30 days, 6 months, 12 months and then once a year from the 2nd to 5th year following surgery. A Doppler ultrasound (DUS) examination is carried out when subjects return to hospital at 6 months following surgery, and a CT angiography (CTA) examination when returning 12 months following surgery, with telephone follow-ups being conducted at 30 days and then once a year from the 2nd to 5th year following surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iliac Artery Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, multi-centre, randomised controlled trial design

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BeGraft Peripheral Stent Graft System

Covered stent

Group Type EXPERIMENTAL

Treatment of primary iliac artery stenosis and/or occlusive lesions

Intervention Type DEVICE

Stent implantation

Bare metal stent system

bare metal stent

Group Type ACTIVE_COMPARATOR

Treatment of primary iliac artery stenosis and/or occlusive lesions

Intervention Type DEVICE

Stent implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment of primary iliac artery stenosis and/or occlusive lesions

Stent implantation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged ≥18 years old, no restrictions in terms of male or female;
* Participating in the trial voluntarily, and having signed the informed consent form;
* TASC class A, B, C or D lesions of the common iliac artery and/or external iliac artery;
* Primary iliac atherosclerotic stenosis and/or occlusive lesions;
* Total length of lesions on the affected side ≤100 mm.

Exclusion Criteria

* Expected survival period \<12 months;
* Pregnant women or those unable to take effective contraceptive measures during the trial;
* Aneurysms present close to the target lesion;
* Acute or subacute thrombosis within the target vessel;
* Previously unobstructed internal iliac artery being blocked (diameter stenosis \<70%) by the stented region;
* Total occlusive lesions, with the guidewire being unable to return the true lumen in the iliac artery;
* Severe calcification at the target lesion, with the catheter being unable to pass;
* Allergic to cobalt-chromium alloy (L605), ePFTE coating material, carbon coating, contrast agent, antiplatelet agents, anticoagulant drugs or presenting with contraindications;
* Total occlusion of the superficial femoral artery and deep femoral artery, with there being no outflow tract;
* Suffering from extensive diffuse disease at the distal end, resulting in poor blood flow in the outflow tract following stent placement;
* A history of coagulation disorders;
* The subject's mental state making it impossible for them to comprehend the nature, extent and possible consequences of the trial, or having a language barrier making it difficult for the subject to give their informed consent;
* Poor cooperation or potentially poor compliance with the protocol which may cause deviations during the trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No